EUROPE-HIGH-GROWTH-FUND
12.2.2024 22:16:25 CET | Business Wire | Press release
European High Growth Opportunities Securitization Fund (the “Fund”), acting through and represented by European High Growth Opportunities Manco SA, each of which is an investment vehicle advised by Alpha Blue Ocean, responds to a press release dated February 1, 2024 issued by Tony G Co-Investment Holdings Ltd. (the “Company”), pursuant to which the Company asserted that it is not bound by its obligations under the terms of the $1,288,000 principal amount convertible debenture of the Company dated August 10, 2021 (the “Debenture”) and purported to issue shares to the Fund.
The Fund would like to notify shareholders of the Company that the Fund rejects the purported share issuance and continues to allege that the Company is bound by, and in breach of, its obligations under the Debenture. The Fund continues to pursue its claim against the Company which will be heard by the Ontario Superior Court of Justice (the “Court”) on November 22, 2024. The Fund reminds both management and the board of directors of the Company that they are bound by their fiduciary obligations to the Company and all stakeholders.
In addition, given the actions of the Company, its management and its board of directors, including Messrs. Antanas Guoga and Ron Akram, the Fund is currently exploring all other avenues of recourse available, including relief under the oppression remedy and relief available from the Canadian Securities Exchange (the “CSE”) and the Ontario Securities Commission with respect to this matter.
In the Fund’s opinion, the Company has failed to provide clear guidance to the market regarding its obligations under the Debenture and the claim that was commenced by the Fund or to comply with its obligations to issue press releases with respect to material changes. The Fund’s position is that:
- As a result of the occurrence of several events of default under the Debenture and the underlying subscription agreement (including the Company’s failure to issue securities to the Fund in a timely manner and the Company’s securities being suspended from trading on the CSE on June 6, 2022), the Fund exercised its rights under the Debenture on November 21, 2022 and demanded the Company immediately pay the sum of $1,288,000 in cash pursuant to the terms of the Debenture;
- Although the monies owed by the Company to the Fund accrue interest at a rate of 40% per annum, compounded monthly, the Company has flouted its obligation to repay the Fund for more than a year, focusing instead on the completion of a series of related party transactions that the Fund believes erode the value of stakeholders for the benefit of insiders;
- On December 7, 2022, the Fund was forced to initiate a proceeding in the Court for, among other things, the payment of $1,288,000, plus interest at the rate of 40% per annum, compounded monthly; and
- In November 2023, the Fund agreed to engage in settlement discussions with the Company and, as an illustration of the Fund’s good faith efforts to resolve the dispute, agreed to extend certain Court deadlines only to have the Company suddenly terminate settlement discussions through the unilateral purported issuance of shares to the Fund and accompanying press release on February 1, 2024, which the Fund believes misrepresents the Company’s liability.
The Fund denies the validity of the share issuance to the Fund and will continue to seek recourse against the Company through its litigation in the Court.
The Fund regrets needing to bring legal proceedings against the Company in order for the Company to comply with its obligations under the Debenture and wishes to put an expeditious end to these distractions.
About European High Growth Opportunities Securitization Fund
European High Growth Opportunities Securitization Fund is a fund based in Luxembourg which is in the business of investing in high growth companies.
Forward-looking statements
This press release contains forward-looking statements. All statements contained in this press release that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words “anticipate,” “believe,” “expect,” “estimate,” “plan,” “intends,” and similar expressions are generally intended to identify forward-looking statements. These statements are based on current expectations of the Fund and currently available information. They are not guarantees of future performance, involve certain risks and uncertainties that are difficult to predict, and are based upon assumptions as to future events that may not prove to be accurate. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Fund’s ability to control or predict, that may cause the actual results to differ materially from those discussed in the forward-looking statements. Forward-looking statements in this press release include, among other things, statements regarding the intentions of the Fund with respect to the Debenture and the litigation (including any potential settlement thereof and the Company’s conduct in connection therewith). Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, that the litigation will be resolved in a manner that is unfavourable to the Company and that the Company will be required to pay amounts or issue shares to the Fund in defending, resolving, or in connection with, the litigation. The forward-looking statements included in this press release are made as of the date of this press release and the Fund does not assume any obligation to update any forward-looking statements contained in this press release, except as required by applicable law.
Neither the CSE nor its regulation services provider accepts responsibility for the adequacy or accuracy of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212603262/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
